CN111936159A - 使用微剂量的稳定胰高血糖素治疗减肥术后低血糖症 - Google Patents

使用微剂量的稳定胰高血糖素治疗减肥术后低血糖症 Download PDF

Info

Publication number
CN111936159A
CN111936159A CN201980009791.5A CN201980009791A CN111936159A CN 111936159 A CN111936159 A CN 111936159A CN 201980009791 A CN201980009791 A CN 201980009791A CN 111936159 A CN111936159 A CN 111936159A
Authority
CN
China
Prior art keywords
glucagon
minutes
analog
vol
glucagon analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980009791.5A
Other languages
English (en)
Chinese (zh)
Inventor
布雷特·纽尼斯万格
史蒂夫·J·普莱斯特斯基
玛丽-伊丽莎白·帕蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Joslin Diabetes Center Inc
Xeris Pharmaceuticals Inc
Original Assignee
Joslin Diabetes Center Inc
Xeris Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joslin Diabetes Center Inc, Xeris Pharmaceuticals Inc filed Critical Joslin Diabetes Center Inc
Publication of CN111936159A publication Critical patent/CN111936159A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201980009791.5A 2018-01-23 2019-01-23 使用微剂量的稳定胰高血糖素治疗减肥术后低血糖症 Pending CN111936159A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862620861P 2018-01-23 2018-01-23
US62/620,861 2018-01-23
PCT/US2019/014815 WO2019147718A1 (en) 2018-01-23 2019-01-23 Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon

Publications (1)

Publication Number Publication Date
CN111936159A true CN111936159A (zh) 2020-11-13

Family

ID=65352189

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980009791.5A Pending CN111936159A (zh) 2018-01-23 2019-01-23 使用微剂量的稳定胰高血糖素治疗减肥术后低血糖症

Country Status (9)

Country Link
US (1) US20210030847A1 (https=)
EP (1) EP3743097A1 (https=)
JP (1) JP7444786B2 (https=)
KR (1) KR20200134213A (https=)
CN (1) CN111936159A (https=)
AU (1) AU2019211352A1 (https=)
BR (1) BR112020014719A2 (https=)
MX (1) MX2020007768A (https=)
WO (1) WO2019147718A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018026899A1 (en) * 2016-08-03 2018-02-08 Joslin Diabetes Center, Inc. Methods and compositions for treating hypoglycemia
US12543982B2 (en) 2021-01-22 2026-02-10 Cilag Gmbh International Method of adjusting a surgical parameter based on biomarker measurements
US12569203B2 (en) * 2021-01-22 2026-03-10 Cilag Gmbh International Bariatric surgery post-surgical monitoring
US12527515B2 (en) 2021-01-22 2026-01-20 Cilag Gmbh International Colorectal surgery post-surgical monitoring
US12128089B2 (en) * 2022-05-26 2024-10-29 Slayback Pharma Llc Stable liquid compositions of glucagon

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933598A (zh) * 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
CN103596583A (zh) * 2011-03-28 2014-02-19 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
CN104662038A (zh) * 2012-07-23 2015-05-27 西兰制药公司 胰高血糖素类似物
WO2016191394A1 (en) * 2015-05-22 2016-12-01 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
WO2016196976A1 (en) * 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
WO2017024285A2 (en) * 2015-08-06 2017-02-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
WO2017053922A1 (en) * 2015-09-25 2017-03-30 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
US20170360892A1 (en) * 2014-12-30 2017-12-21 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2683364B1 (en) 2011-03-10 2017-01-18 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
DK3102184T3 (da) 2014-02-06 2019-05-06 Xeris Pharmaceuticals Inc Stabile formuleringer af peptider og fremgangsmåder til fremstilling
GB201710822D0 (en) * 2017-07-05 2017-08-16 Zealand Pharma As Methods and medical uses relating to the treatment of hypoglycaemia

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102933598A (zh) * 2010-03-26 2013-02-13 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
CN103596583A (zh) * 2011-03-28 2014-02-19 诺沃—诺迪斯克有限公司 新型胰高血糖素类似物
CN104662038A (zh) * 2012-07-23 2015-05-27 西兰制药公司 胰高血糖素类似物
US20170360892A1 (en) * 2014-12-30 2017-12-21 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
WO2016191394A1 (en) * 2015-05-22 2016-12-01 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with glp-1 antagonists
WO2016196976A1 (en) * 2015-06-04 2016-12-08 Xeris Pharmaceuticals, Inc. Glucagon delivery apparatuses and related methods
WO2017024285A2 (en) * 2015-08-06 2017-02-09 Xoma (Us) Llc Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
WO2017053922A1 (en) * 2015-09-25 2017-03-30 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FLORENCIA HALPERIN，等: "Glucagon treatment for post-Gastric Bypass Hypoglycemia", OBESITY, vol. 18, no. 9, pages 1858, XP009512618, DOI: 10.1038/oby.2010.15 *
覃婷婷;白海娇;黄哲;: "胰高血糖素样肽-1及其相关药物研究进展", 药学进展, vol. 41, no. 12, pages 926 - 933 *

Also Published As

Publication number Publication date
JP2021511386A (ja) 2021-05-06
BR112020014719A2 (pt) 2020-12-08
MX2020007768A (es) 2020-11-12
WO2019147718A8 (en) 2020-08-06
AU2019211352A1 (en) 2020-07-30
EP3743097A1 (en) 2020-12-02
KR20200134213A (ko) 2020-12-01
WO2019147718A1 (en) 2019-08-01
US20210030847A1 (en) 2021-02-04
JP7444786B2 (ja) 2024-03-06

Similar Documents

Publication Publication Date Title
US20240207365A1 (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
JP7444786B2 (ja) 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置
US20240238381A1 (en) Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
US12514907B2 (en) Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes
WO2016196976A1 (en) Glucagon delivery apparatuses and related methods
CA3174711C (en) Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same
HK40101667A (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
HK40101667B (en) Methods for producing stable therapeutic formulations in aprotic polar solvents
BR112019010236B1 (pt) Formulações tamponadas de exendina (9-39) e uso das mesmas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20201113

WD01 Invention patent application deemed withdrawn after publication